China’s 30-Day IND Review Pathway Could Reshape Global

What Is China’s 30-Working-Day IND Pathway?

China generally requires a clinical trial application before an investigational medicine can be tested in people. Under the established implied-approval framework, a sponsor may proceed if regulators raise no objection within the applicable review period, commonly described as 60 working days. The newly reported pathway would shorten that target to 30 working days for qualifying applications.

This is permission to begin a clinical investigation, not marketing authorization or proof that a medicine works. Regulators can still request information, pause the review or prevent a trial from starting when safety, manufacturing or protocol concerns remain unresolved. Sponsors should confirm the pathway’s current eligibility criteria and procedural requirements directly with the National Medical Products Administration and its Center for Drug Evaluation.

How Could Faster IND Review Affect Drug Development?

Regulatory review can influence when trial sites activate, particularly in multi-regional studies where countries begin enrollment on different schedules. Earlier participation could improve access to experimental treatments and generate evidence from Chinese patients alongside data collected elsewhere. This may be especially important in rapidly evolving fields such as oncology, rare diseases and precision medicine.

Speed alone does not guarantee faster access to an approved treatment. Ethics review, hospital contracting, investigator training, laboratory preparation and patient recruitment can all delay a study after regulatory clearance. Development timelines also depend on whether the treatment demonstrates an acceptable balance of benefits and harms in appropriately designed trials.

What Makes a Clinical Trial Application China-Ready?

A strong application should contain coherent evidence on pharmacology, toxicology, manufacturing quality, dose selection and foreseeable risks. The protocol should define eligibility criteria, safety monitoring, stopping rules and plans for reporting serious adverse events. Translating documents late or submitting inconsistent global and local materials can create questions that offset the benefit of an accelerated review target.

International Council for Harmonisation guidance recommends planning multi-regional trials so that treatment effects can be interpreted across participating populations. Sponsors may need to consider genetic, physiological, dietary, medical-practice and other factors that could influence how a medicine behaves. These considerations do not automatically require a separate development program, but they should be addressed prospectively rather than after a global protocol has been finalized.